2016-02-18 |
151 |
|
Entry of Summary Judgment Concerning U.S. Patent No. 8,759,350, Certification of Judgment Under Rule 54…2014
18 October 2017
1:14-cv-03168
830 Patent
None
District Court, D. New Jersey |
External link to document |
2015-10-13 |
169 |
|
7,053,092 (“the ’092 patent”), 8,017,615 (“the ’615 patent”),
8,580,796 (“the ’796 patent”), 8,…’600 patent”),
8,642,760 (“the ’760 patent”), and 8,759,350 (“the ’350 patent”
or the “Patent”). The…drug claimed in a patent or the use of which is
claimed in a patent” prior to the patent’s expiration. …various patents
covering Otsuka’s brand name aripiprazole product, Abilify®. 1
1 The patents asserted…actions specifically
include: U.S. Patent Nos. 5,006,528 (“the ’528 patent”),
Case 1:14-cv-03168-JBS-KMW Document |
External link to document |
2016-02-18 |
218 |
|
Entry of Summary Judgment Concerning U.S. Patent No. 8,759,350, Certification of Judgment Under Rule 54…2014
18 October 2017
1:14-cv-03168
830 Patent
None
District Court, D. New Jersey |
External link to document |
2016-04-12 |
240 |
|
5,006,528 (“the ’528
patent”), 7,053,092 (“the ’092 patent”), 8,017,615 (“the ’615
patent”), 8,580,796 (“…(“the ’796 patent”), 8,642,600 (“the ’600
patent”), and 8,642,760 (“the ’760 patent”).
…asserted claims of U.S.
Patent No. 8,759,350 (hereinafter, “the ’350 patent”), to mean
“a single dosage… 1 The patents asserted in these related infringement actions
generally include: U.S. Patent Nos. 5,…series of related
patents: three directed at Otsuka’s aripiprazole polymorph
patents (the ’615, the ’ |
External link to document |